Abby Hardy, Author at BioTuesdays

Developments

Kane Biotech recommences trading on the OTCQB

Kane Biotech’s (TSX-V:KNE) shares will recommence trading on the OTCQB Venture Market on May 19, 2020. Kane Biotech’s shares have been trading under the Pink Open Market since Feb. 4, 2019. With the upgrade to the...

May 19, 2020

Developments

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) is planning to commence a Phase 2a trial of CRV431 for the treatment of NASH fibrosis in June. The study, called AMBITION, will enroll 18 adults with presumed NASH F2- or F3-stage...

May 19, 2020

Developments

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Cassava Sciences (NASDAQ:SAVA) reported disappointing topline results from its Phase 2b study of PTI-125 for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85...

May 15, 2020

Developments

Capricor reports positive topline data from Phase 2 DMD trial

Capricor Therapeutics (NASDAQ:CAPR) reported positive topline 12-month results of its Phase 2 clinical trial of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002-treated patients demonstrated...

May 13, 2020

Developments

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

AVROBIO (NASDAQ:AVRO) updated data on its Phase 2 and Phase 1/2 trials evaluating its lentiviral-based gene therapies for the treatment of Fabry disease and cystinosis, respectively. Fabry disease is a genetic disease...

May 13, 2020

Developments

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

Gamida Cell (NASDAQ:GMDA) reported positive topline results from its Phase 3 study of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant. The study achieved its primary...

May 12, 2020

Developments

CytoSorbents gets EU approval for CytoSorb

The European Union approved CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. Rivaroxaban is a...

May 12, 2020

Developments

Helius’ PoNS treatment gets FDA breakthrough designation for MS

Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) portable neuromodulation stimulator (PoNS) received FDA breakthrough designation for the treatment of gait deficit due to symptoms of multiple sclerosis (MS). The non...

May 12, 2020

Developments

Imagin Medical supports Bladder Cancer Awareness Month

This month, Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will be undertaking a number of efforts and activities to help raise awareness about bladder cancer. Imagin has created and will...

May 12, 2020

Developments

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) reported positive results from its consumer product test evaluating the efficacy of its new shampoo on dermatitis and dandruff. The shampoo was developed based on research indicating that...

May 12, 2020

Author - Abby Hardy

Kane Biotech recommences trading on the OTCQB

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Capricor reports positive topline data from Phase 2 DMD trial

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

CytoSorbents gets EU approval for CytoSorb

Helius’ PoNS treatment gets FDA breakthrough designation for MS

Imagin Medical supports Bladder Cancer Awareness Month

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

General

More